In a regulatory filing, Dyne Therapeutics (DYN) disclosed that its CEO John Cox bought 100K shares of common stock on July 14th in a total transaction size of $911K. Shares are up 9% at $8.99 afterhours.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DYN:
- Dyne Therapeutics price target lowered to $41 from $46 at Evercore ISI
- Dyne Therapeutics’ DYNE-251 Study Update: A Potential Game-Changer for Duchenne Muscular Dystrophy
- Dyne Therapeutics Announces $200M Public Offering
- Morning Movers: Tesla dips as Musk and Trump resume feud
- Dyne Therapeutics 24.2M share Spot Secondary priced at $8.25